Pfizer Announced Jeffrey Legos As Their New Chief Oncology Officer
Pfizer Inc. announced that Jeffrey Legos, PhD, MBA, will assume the role of Chief Oncology Officer, replacing the interim Chief, Roger Dansey, M.D.
Jeffrey Legos, PhD, MBA, is a seasoned pharmaceutical executive with over two decades of experience in oncology drug development. He earned his PhD in physiology from Temple University School of Medicine and an MBA in Finance from the Villanova University School of Business. He completed post-graduate fellowship training in pharmacology and pharmaceutical medicine.
Legos began his career at GlaxoSmithKline (GSK), where he held various leadership positions, including Vice President and Global Medicines Development Leader in Oncology.
During his tenure at GSK, he led the development of Tafinlar® (dabrafenib) and Mekinist® (trametinib) as single agents and in combination therapies for patients with BRAF V600 mutations, as well as Promacta®/Revolade® (eltrombopag) for thrombocytopenia across multiple diseases.
In 2015, Dr. Legos joined Novartis as Executive Vice President and Global Head of Oncology and Hematology Development. In this role, he was responsible for leading the development, registration, approval, and lifecycle management of a diverse portfolio encompassing targeted therapies, immuno-oncology, radioligand therapies, and cell and gene therapies.
In February 2025, Dr. Legos was appointed as Chief Oncology Officer at Pfizer Inc., where he will lead the company’s Oncology Research & Development, overseeing all functions from pre-clinical to late-stage clinical development activities.
Throughout his career, Dr. Legos has authored over 40 manuscripts and numerous abstracts published in peer-reviewed journals. He serves as a scientific advisor to the Melanoma Research Alliance and has been involved with industry-wide oncology task forces for organizations such as Friends of Cancer Research and LUNGevity.
About Pfizer Oncology
Pfizer Oncology is dedicated to advancing cancer treatment through innovative research and the development of transformative therapies. Over the past decade, the company has adopted bold approaches to translate scientific discoveries into effective medicines for individuals living with cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023